HALIFAX, NOVA SCOTIA--(Marketwire - May 31, 2011) - Immunovaccine Inc. (TSX VENTURE:IMV), a clinical stage vaccine developer, announced today that it will provide a clinical update at the BioFinance Conference on June 1, 2011. The Company will also attend the annual meeting of the American Society of Clinical Oncology (ASCO), June 4-7, 2011. An Immunovaccine representative has been asked to be a panellist at the European Biopharmaceutical Conference on June 16, 2011.

BioFinance Conference – Presentation

At the BioFinance Conference Dr. Marc Mansour, Immunovaccine's Chief Operating Officer and Chief Science Officer, will make a corporate presentation on Wednesday, June 1, 2011, at 9:45 a.m. E.T. in Room 2 of the St. Andrew's Club & Conference Centre in Toronto, Canada. The presentation will include an update on the Phase I clinical trial results of DPX-0907, the Company's therapeutic cancer vaccine targeting patients with breast, ovarian and prostate cancer. Dr. Mansour will also provide a corporate update and overview of the Company's pipeline and research activities.

ASCO Conference – Abstracts #e13050 and #2515

At ASCO 2011, Immunovaccine's abstract #: e13050, titled: A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer can be viewed at www.asco.org in a fully searchable format.

DPX-0907 combines seven peptide antigens plus an adjuvant with Immunovaccine's DepoVax™ delivery and enhancement platform. This first-in-human trial has generated important safety and immunogenicity information that will aid in the rational design of future DPX-0907 cancer vaccine trials and support the future use of DepoVax™ for delivering multi-peptide based vaccines.

An additional ASCO abstract #2515, describing the Survivac vaccine candidate in-licensed by Immunovaccine, will be a poster presentation titled: First-in-human trial focusing on the immunologic effects of the survivin-derived multiepitope vaccine EMD 640744. The data from this Phase I clinical trial conducted by Merck KGaA is scheduled to be presented at the ASCO conference on Saturday, June 4, 2011 from 12:00-1:00 pm C.T. as part of the poster discussion session under the Developmental Therapeutics - Clinical Pharmacology and Immunotherapy track.

Immunovaccine obtained the exclusive worldwide licensing rights for EMD 640744 from Merck KGaA. EMD 640744 is an investigational therapeutic survivin-based cancer vaccine designed to target multiple solid tumors and hematological malignancies. Immunovaccine is building on the current Phase I clinical trial for EMD 640744 by formulating the survivin-based vaccine in its DepoVax™ delivery platform to create DPX-Survivac. The Company is preparing DPX-Survivac for clinical trials targeting ovarian cancer.

Dr. Marc Mansour will attend the ASCO conference from June 3-7, 2011 in Chicago. The ASCO conference is a prominent scientific meeting for cancer research, attracting approximately 30,000 attendees each year.

European Biopharmaceutical Conference – Panelist

Dr. Marc Mansour has been invited to be an expert panelist at the European Biopharmaceutical Conference on June 16, 2011 in Cannes, France. This conference invites biotech CEOs from Europe and the U.S. to gather with senior executives from the major pharmaceutical and big biotech companies, to explore new business opportunities.

About Immunovaccine Inc.

Immunovaccine Inc. (TSX VENTURE:IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology and product candidates. The Company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.